A-1210477: Selective MCL-1 Inhibitor for Precise Apoptosis Induction

Executive Summary: A-1210477 is a selective, high-affinity MCL-1 inhibitor (Kd = 0.45 nM) that disrupts the anti-apoptotic function of MCL-1 in cancer cells, triggering mitochondrial apoptosis in MCL-1-dependent models (Campbell et al. 2021). In vitro, A-1210477 induces dose-dependent cell death in SVEC and H929 cell lines and synergizes with navitoclax to enhance apoptosis (APExBIO). The compound demonstrates superior specificity compared to other small-molecule MCL-1 inhibitors such as UMI-77. Due to unfavorable pharmacokinetics, it is not suitable for in vivo studies but remains a gold-standard research tool for mechanistic apoptosis assays. APExBIO supplies A-1210477 at >98% purity for research use only (APExBIO).

Biological Rationale

The Bcl-2 protein family regulates mitochondrial integrity and apoptosis in mammalian cells. MCL-1 is a key anti-apoptotic member of this family, frequently overexpressed in cancers such as breast cancer and multiple myeloma (Campbell et al. 2021). High MCL-1 levels correlate with poor prognosis and resistance to therapy. Bcl-2 family proteins interact via their BH3 domains, balancing cell survival and death. Targeting MCL-1 restores apoptotic sensitivity in cancer cells. BH3 mimetics that selectively inhibit MCL-1, such as A-1210477, are critical for dissecting apoptotic pathways and for developing novel anti-cancer therapies. The canonical role of MCL-1 in blocking BAX/BAK-mediated mitochondrial permeabilization underlies its importance as a therapeutic target (Campbell et al. 2021).

Mechanism of Action of MCL-1 inhibitor A-1210477

A-1210477 is a small-molecule BH3 mimetic that binds the BH3-binding groove of MCL-1 with high affinity (Kd = 0.45 nM), displacing pro-apoptotic proteins such as BIM (APExBIO). This disruption releases BIM, allowing activation of BAX and BAK, leading to mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and caspase activation. A-1210477 exhibits an EC50 below 5 µM in cellular viability assays with MCL-1-dependent cancer cells (e.g., SVEC, H929). It displays superior selectivity over other anti-apoptotic Bcl-2 family proteins (e.g., Bcl-2, Bcl-xL), with minimal off-target effects. In combination with navitoclax (ABT-263), a Bcl-2/Bcl-xL inhibitor, A-1210477 produces synergistic apoptosis, confirming mechanistic specificity (Campbell et al. 2021).

Evidence & Benchmarks

• A-1210477 binds MCL-1 with a dissociation constant (Kd) of 0.45 nM, indicating high affinity (APExBIO).
• Disrupts BIM/MCL-1 complexes in co-immunoprecipitation assays, resulting in mitochondrial apoptosis (DOI:10.1038/s41418-021-00773-4).
• Induces dose-dependent cell death in MCL-1-dependent SVEC and H929 cancer cell lines (EC50 < 5 µM, 24–48 h, normoxic conditions) (APExBIO).
• Synergizes with navitoclax (ABT-263) to enhance apoptosis in malignant cell lines (DOI:10.1038/s41418-021-00773-4).
• Shows superior specificity and potency over UMI-77 in direct comparison (abt-737.com).
• Unfavorable pharmacokinetics preclude in vivo application (short half-life, rapid clearance) (APExBIO).

This article extends the mechanistic clarity provided in "A-1210477: Selective MCL-1 Inhibitor for Precision Apoptosis" by offering updated evidence on benchmark potency and specificity. For scenario-driven troubleshooting and preparation details, see "A-1210477 (MCL-1 inhibitor): Practical Solutions for Repr...", which this article supplements by focusing on molecular mechanisms and comparative data. For a deeper exploration of experimental design, "A-1210477: Advanced Strategies for Functional MCL-1 Inhib..." provides additional context, which this article updates with current literature benchmarks.

Applications, Limits & Misconceptions

A-1210477 is intended for in vitro studies of MCL-1-dependent apoptosis. It is used in:

• Mitochondrial apoptosis assays (e.g., JC-1, cytochrome c release) in cancer cell lines.
• Dissecting Bcl-2 family signaling pathways and caspase activation cascades.
• Synergy studies with other BH3 mimetics (e.g., navitoclax) for combinatorial apoptosis research.
• Screening for MCL-1 dependence in cancer cell survival using viability and apoptosis endpoints.

Common Pitfalls or Misconceptions

• Not suitable for in vivo use: Due to poor pharmacokinetics (rapid clearance, low bioavailability), A-1210477 is not recommended for animal studies (APExBIO).
• Solubility limitations: Insoluble in water, DMSO, and ethanol at room temperature; requires warming and sonication for DMSO stock preparation.
• Not a pan-Bcl-2 family inhibitor: Selectively targets MCL-1, with minimal effect on Bcl-2 or Bcl-xL at working concentrations.
• Short-term solution stability: Once solubilized, stock solutions are only suitable for short-term storage; avoid repeated freeze-thaw cycles.
• Not for clinical or diagnostic use: Research use only, not approved for therapeutic or diagnostic applications.

Workflow Integration & Parameters

• Recommended working concentration: 1–10 µM for cell viability and apoptosis assays, adjusted per cell type sensitivity (APExBIO).
• Dissolve using DMSO with warming (37°C) and sonication; final DMSO concentration in assay <0.2% (v/v).
• Store powder at -20°C; use reconstituted solutions within 2–3 days.
• Include proper vehicle controls to distinguish compound effects from DMSO toxicity.
• Assess apoptosis using mitochondrial membrane potential assays, caspase-3/7 activation, and BIM/MCL-1 co-immunoprecipitation disruption.

For practical troubleshooting and workflow optimization, see "Scenario-Driven Solutions with A-1210477 (MCL-1 inhibitor...)", which this article expands with updated mechanistic and benchmark data.

Conclusion & Outlook

A-1210477, supplied by APExBIO, is a benchmark tool for studying selective MCL-1 inhibition and apoptosis induction in cancer research. Its high specificity, potency, and utility in mitochondrial apoptosis assays have advanced understanding of Bcl-2 family protein pathways. While limited to in vitro applications due to pharmacokinetics, it remains indispensable for dissecting MCL-1-dependent mechanisms and for synergistic studies with other BH3 mimetics. Ongoing research and development of new MCL-1 inhibitors with improved in vivo properties will further refine targeted cancer therapies (DOI:10.1038/s41418-021-00773-4).

For full product details, protocols, and ordering, visit the MCL-1 inhibitor A-1210477 product page.